According to the research report, the global USliquid biopsy market size is expected to touch USD 1,816.95 million by 2032, from USD 362.82 million in 2022, growing with a significant CAGR of 17.48% from 2022 to 2032.
The US liquid biopsy market report offers a
comprehensive study of the current state expected at the major drivers, market
strategies, and key vendors’ growth. The report presents energetic visions to
conclude and study the market size, market hopes, and competitive surroundings.
The research also focuses on the important achievements of the market, research
& development, and regional growth of the leading competitors operating in
the market. The current trends of the global US liquid biopsy market in
conjunction with the geographical landscape of this vertical have also been
included in this report.
The report offers intricate dynamics about
different aspects of the global US liquid biopsy market, which aids companies operating
in the market in making strategic development decisions. The study also
elaborates on significant changes that are highly anticipated to configure
growth of the global US liquid biopsy market during the forecast period. It
also includes a key indicator assessment that highlights growth prospects of this
market and estimates statistics related to growth of the market in terms of
value (US$ Mn) and volume (tons).
Sample
Link @ https://www.precedenceresearch.com/sample/2474
| Report Coverage | Details |
| Market Size in 2022 | USD 362.82 Million |
| Market Size by 2032 | USD 1,816.95 Million |
| Growth Rate from 2023 to 2032 | CAGR of 17.48% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Biomarker Types, By Application, By Sample, By End User |
This study covers a detailed segmentation
of the global US liquid biopsy market, along with key information and a
competition outlook. The report mentions company profiles of players that are
currently dominating the global US liquid biopsy market, wherein various
developments, expansions, and winning strategies practiced and implemented by
leading players have been presented in detail.
Key Players
- ANGLE plc, Biocept Inc.
- Bio-Rad Laboratories Inc.
- Epigenomics AG
- Exact Sciences Corporation
- F. Hoffmann-La Roche AG
- Guardant Health Inc.
- Illumina Inc.
- MDxHealth SA
- Menarini Silicon Biosystems
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
Market Segmentation
- Circulating Tumor Cells (CTCs)
- Circulating Tumor DNA (CTDNA)
- Extracellular vesicles (EVS)
- Other Biomarkers
By Application
- Cancer Therapeutic Application
- Reproductive Health
- Other Therapeutic Application
By Sample
- Blood Sample
- Urine Sample
- Other
By End User
- Hospitals and Laboratories
- Academic and Research Centers
- Other End Users
Research Methodology
The research methodology adopted by
analysts for compiling the global US liquid biopsy market report is based on
detailed primary as well as secondary research. With the help of in-depth
insights of the market-affiliated information that is obtained and legitimated
by market-admissible resources, analysts have offered riveting observations and
authentic forecasts for the global market.
During the primary research phase, analysts
interviewed market stakeholders, investors, brand managers, vice presidents,
and sales and marketing managers. Based on data obtained through interviews of
genuine resources, analysts have emphasized the changing scenario of the global
market.
For secondary research, analysts
scrutinized numerous annual report publications, white papers, market
association publications, and company websites to obtain the necessary
understanding of the global US liquid biopsy market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on US Liquid Biopsy Market
5.1. COVID-19 Landscape: US Liquid Biopsy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. US Liquid Biopsy Market, By Biomarker Types
8.1. US Liquid Biopsy Market, by Biomarker Types, 2023-2032
8.1.1. Circulating Tumor Cells (CTCs)
8.1.1.1. Market Revenue and Forecast (2023-2032)
8.1.2. Circulating Tumor DNA (CTDNA)
8.1.2.1. Market Revenue and Forecast (2023-2032)
8.1.3. Extracellular vesicles (EVS)
8.1.3.1. Market Revenue and Forecast (2023-2032)
8.1.4. Other Biomarkers
8.1.4.1. Market Revenue and Forecast (2023-2032)
Chapter 9. US Liquid Biopsy Market, By Application
9.1. US Liquid Biopsy Market, by Application, 2023-2032
9.1.1. Cancer Therapeutic Application
9.1.1.1. Market Revenue and Forecast (2023-2032)
9.1.2. Reproductive Health
9.1.2.1. Market Revenue and Forecast (2023-2032)
9.1.3. Other Therapeutic Application
9.1.3.1. Market Revenue and Forecast (2023-2032)
Chapter 10. US Liquid Biopsy Market, By Sample
10.1. US Liquid Biopsy Market, by Sample, 2023-2032
10.1.1. Blood Sample
10.1.1.1. Market Revenue and Forecast (2023-2032)
10.1.2. Urine Sample
10.1.2.1. Market Revenue and Forecast (2023-2032)
10.1.3. Other
10.1.3.1. Market Revenue and Forecast (2023-2032)
Chapter 11. US Liquid Biopsy Market, By End User
11.1. US Liquid Biopsy Market, by End User, 2023-2032
11.1.1. Hospitals and Laboratories
11.1.1.1. Market Revenue and Forecast (2023-2032)
11.1.2. Academic and Research Centers
11.1.2.1. Market Revenue and Forecast (2023-2032)
11.1.3. Other End Users
11.1.3.1. Market Revenue and Forecast (2023-2032)
Chapter 12. US Liquid Biopsy Market, Regional Estimates and Trend Forecast
12.1. U.S.
12.1.1. Market Revenue and Forecast, by Biomarker Types (2023-2032)
12.1.2. Market Revenue and Forecast, by Application (2023-2032)
12.1.3. Market Revenue and Forecast, by Sample (2023-2032)
12.1.4. Market Revenue and Forecast, by End User (2023-2032)
Chapter 13. Company Profiles
13.1. ANGLE plc, Biocept Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bio-Rad Laboratories Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Epigenomics AG
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Exact Sciences Corporation
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. F. Hoffmann-La Roche AG
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Guardant Health Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Illumina Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. MDxHealth SA
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Menarini Silicon Biosystems
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. QIAGEN N.V.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1
774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments